Brivaracetam for the treatment of epilepsy

J 2016

Brivaracetam for the treatment of epilepsy

KLEIN, Pavel, Ivana TYRLÍKOVÁ, Milan BRÁZDIL a Ivan REKTOR

Základní údaje

Originální název

Brivaracetam for the treatment of epilepsy

Autoři

KLEIN, Pavel (840 Spojené státy), Ivana TYRLÍKOVÁ (203 Česká republika), Milan BRÁZDIL (203 Česká republika) a Ivan REKTOR (203 Česká republika, garant, domácí)

Vydání

EXPERT OPINION ON PHARMACOTHERAPY, Abingdon, TAYLOR & FRANCIS LTD, 2016, 1465-6566

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.894

Kód RIV

RIV/00216224:14740/16:00090504

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1517/14656566.2016.1135129

UT WoS

000370165600001

Klíčová slova anglicky

Synaptic vesicle protein 2A ligand; Brivaracetam; anticonvulsant agent; partial-onset seizures; refractory epilepsy

Štítky

rivok

Změněno: 11. 8. 2016 14:29, Mgr. Eva Špillingová

Anotace

V originále

Introduction: Approximately one third of patients with epilepsy fail to respond to existing medications. Levetiracetam is an effective antiepileptic drug (AED) postulated to act by binding to synaptic vesicle protein 2A. Brivaracetam is a novel high affinity SV2A ligand with approximately 20-fold higher affinity for SV2A protein than levetiracetam. It is at an advanced stage of clinical development for treatment of epilepsy.Areas covered: This article reviews animal data, pharmacokinetics, and phase 1-3 data of Brivaracetam treatment of epilepsy. Brivaracetam has broad-spectrum anticonvulsant activity in animal models.Expert Opinion: Phase 1 studies indicated that single oral doses of 5-800 mg and repeated oral doses of up to 600 mg were well tolerated and showed favorable pharmacokinetic profile. Phase 2 studies indicated good safety and tolerability of brivaracetam in the dose range of 5-150 mg/day and provided proof of concept for efficacy in treating refractory partial onset seizures. Efficacy and safety have been evaluated in 4 phase 3 studies with dose range of 5-200 mg which have demonstrated efficacy in the range of 100-200 mg/day dose and, in most studies, also with 50 mg/day dose, and good safety and tolerability profile across 5-200 mg doses in adjunctive treatment of refractory partial onset seizures.

Přiložené soubory

EL_1350892_Brivaracetam_for_the_treatment_of_epilepsy.pdf

Požádat o autorskou verzi souboru

Citovat

KLEIN, Pavel, Ivana TYRLÍKOVÁ, Milan BRÁZDIL a Ivan REKTOR. Brivaracetam for the treatment of epilepsy. EXPERT OPINION ON PHARMACOTHERAPY. Abingdon: TAYLOR & FRANCIS LTD, 2016, roč. 17, č. 2, s. 283-295. ISSN 1465-6566. Dostupné z: https://dx.doi.org/10.1517/14656566.2016.1135129.

@article{1350892,
   author = {Klein, Pavel and Tyrlíková, Ivana and Brázdil, Milan and Rektor, Ivan},
   article_location = {Abingdon},
   article_number = {2},
   doi = {http://dx.doi.org/10.1517/14656566.2016.1135129},
   keywords = {Synaptic vesicle protein 2A ligand; Brivaracetam; anticonvulsant agent; partial-onset seizures; refractory epilepsy},
   language = {eng},
   issn = {1465-6566},
   journal = {EXPERT OPINION ON PHARMACOTHERAPY},
   title = {Brivaracetam for the treatment of epilepsy},
   url = {http://www.tandfonline.com/doi/full/10.1517/14656566.2016.1135129},
   volume = {17},
   year = {2016}
}

TY  - JOUR
ID  - 1350892
AU  - Klein, Pavel - Tyrlíková, Ivana - Brázdil, Milan - Rektor, Ivan
PY  - 2016
TI  - Brivaracetam for the treatment of epilepsy
JF  - EXPERT OPINION ON PHARMACOTHERAPY
VL  - 17
IS  - 2
SP  - 283-295
EP  - 283-295
PB  - TAYLOR & FRANCIS LTD
SN  - 14656566
KW  - Synaptic vesicle protein 2A ligand
KW  - Brivaracetam
KW  - anticonvulsant agent
KW  - partial-onset seizures
KW  - refractory epilepsy
UR  - http://www.tandfonline.com/doi/full/10.1517/14656566.2016.1135129
L2  - http://www.tandfonline.com/doi/full/10.1517/14656566.2016.1135129
N2  - Introduction: Approximately one third of patients with epilepsy fail to respond to existing medications. Levetiracetam is an effective antiepileptic drug (AED) postulated to act by binding to synaptic vesicle protein 2A. Brivaracetam is a novel high affinity SV2A ligand with approximately 20-fold higher affinity for SV2A protein than levetiracetam. It is at an advanced stage of clinical development for treatment of epilepsy.Areas covered: This article reviews animal data, pharmacokinetics, and phase 1-3 data of Brivaracetam treatment of epilepsy. Brivaracetam has broad-spectrum anticonvulsant activity in animal models.Expert Opinion: Phase 1 studies indicated that single oral doses of 5-800 mg and repeated oral doses of up to 600 mg were well tolerated and showed favorable pharmacokinetic profile. Phase 2 studies indicated good safety and tolerability of brivaracetam in the dose range of 5-150 mg/day and provided proof of concept for efficacy in treating refractory partial onset seizures. Efficacy and safety have been evaluated in 4 phase 3 studies with dose range of 5-200 mg which have demonstrated efficacy in the range of 100-200 mg/day dose and, in most studies, also with 50 mg/day dose, and good safety and tolerability profile across 5-200 mg doses in adjunctive treatment of refractory partial onset seizures.
ER  -

KLEIN, Pavel, Ivana TYRLÍKOVÁ, Milan BRÁZDIL a Ivan REKTOR. Brivaracetam for the treatment of epilepsy. \textit{EXPERT OPINION ON PHARMACOTHERAPY}. Abingdon: TAYLOR \&{} FRANCIS LTD, 2016, roč.~17, č.~2, s.~283-295. ISSN~1465-6566. Dostupné z: https://dx.doi.org/10.1517/14656566.2016.1135129.

Podrobný výpis o publikaci